Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 12:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–10 of 10 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed Phase 1 Interventional Accepts healthy volunteers

Multiple Dose Ethnobridging PK Study in Healthy Subjects

NCT03750565
Conditions
Inflammatory Bowel Diseases, IBD
Interventions
TD-1473 - Dose A, TD-1473 - Dose B, TD-1473 - Dose C, Placebo
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cypress, California
Terminated Phase 2Phase 3 Interventional Results available

Efficacy & Safety of TD-1473 in Ulcerative Colitis

NCT03758443
Conditions
Ulcerative Colitis (UC)
Interventions
TD-1473 Dose A, TD-1473 Dose B, TD-1473 Dose C, Placebo
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
18 Years and older
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
38
States / cities
Chula Vista, California • La Jolla, California • Lancaster, California + 34 more
Conditions
Intestinal Disorder, Bowel Diseases, Inflammatory
Interventions
TD-1473 [Tablet A], TD-1473 [Tablet B]
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
19 Years to 55 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
2
States / cities
Cypress, California • Lincoln, Nebraska
Conditions
Inflammatory Bowel Disease
Interventions
TD-1473, Itraconazole
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
19 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Lincoln, Nebraska
Terminated Phase 2Phase 3 Interventional Results available

TD-1473 Long-Term Safety (LTS) Ulcerative Colitis (UC) Study

NCT03920254
Conditions
Ulcerative Colitis (UC)
Interventions
TD-1473 Dose A, TD-1473 Dose B, TD-1473 Dose C
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
36
States / cities
Chula Vista, California • Lancaster, California • Orange, California + 32 more
Conditions
Healthy
Interventions
TD-1473 for SAD, Placebo for SAD, TD-1473 for MAD, Placebo for MAD
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
19 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Lincoln, Nebraska
Terminated Phase 2 Interventional Results available

Efficacy and Safety of TD-1473 in Crohn's Disease

NCT03635112
Conditions
Crohn's Disease
Interventions
Placebo, TD-1473
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
44
States / cities
Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 39 more
Conditions
Intestinal Disorders, Bowel Diseases, Inflammatory
Interventions
TD-1473 oral capsule, [14C]-TD-1473 IV bolus, [14C]-TD-1473 Oral Capsule
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
19 Years to 55 Years · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Lincoln, Nebraska
Terminated Phase 2 Interventional Results available

Rifaximin in Patients With Diabetic Gastroparesis

NCT04254549
Conditions
Crohn Disease, Diabetic Gastroparesis
Interventions
Rifaximin, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Jacksonville, Florida
Conditions
Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe
Interventions
TD-1473, Placebo
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
5
States / cities
Scottsdale, Arizona • Monroe, Louisiana • Hermitage, Tennessee + 2 more